Does PetMed Express, Inc. (NASDAQ:PETS) Have A Good P/E Ratio?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). We’ll show how you can use PetMed Express, Inc.’s (NASDAQ:PETS) P/E ratio to inform your assessment of the investment opportunity. Based on the last twelve months, PetMed Express’s P/E ratio is 11.59. That means that at current prices, buyers pay $11.59 for every $1 in trailing yearly profits.

See our latest analysis for PetMed Express

How Do You Calculate A P/E Ratio?

The formula for price to earnings is:

Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Or for PetMed Express:

P/E of 11.59 = $23.43 ÷ $2.02 (Based on the year to December 2018.)

Is A High P/E Ratio Good?

A higher P/E ratio implies that investors pay a higher price for the earning power of the business. That isn’t necessarily good or bad, but a high P/E implies relatively high expectations of what a company can achieve in the future.

How Growth Rates Impact P/E Ratios

Probably the most important factor in determining what P/E a company trades on is the earnings growth. When earnings grow, the ‘E’ increases, over time. Therefore, even if you pay a high multiple of earnings now, that multiple will become lower in the future. A lower P/E should indicate the stock is cheap relative to others — and that may attract buyers.

Most would be impressed by PetMed Express earnings growth of 19% in the last year. And earnings per share have improved by 17% annually, over the last five years. So one might expect an above average P/E ratio.

How Does PetMed Express’s P/E Ratio Compare To Its Peers?

We can get an indication of market expectations by looking at the P/E ratio. We can see in the image below that the average P/E (28.4) for companies in the online retail industry is higher than PetMed Express’s P/E.

NasdaqGS:PETS Price Estimation Relative to Market, April 12th 2019
NasdaqGS:PETS Price Estimation Relative to Market, April 12th 2019

PetMed Express’s P/E tells us that market participants think it will not fare as well as its peers in the same industry. Since the market seems unimpressed with PetMed Express, it’s quite possible it could surprise on the upside. If you consider the stock interesting, further research is recommended. For example, I often monitor director buying and selling.

Don’t Forget: The P/E Does Not Account For Debt or Bank Deposits

Don’t forget that the P/E ratio considers market capitalization. In other words, it does not consider any debt or cash that the company may have on the balance sheet. Hypothetically, a company could reduce its future P/E ratio by spending its cash (or taking on debt) to achieve higher earnings.

Spending on growth might be good or bad a few years later, but the point is that the P/E ratio does not account for the option (or lack thereof).

Is Debt Impacting PetMed Express’s P/E?

PetMed Express has net cash of US$93m. This is fairly high at 19% of its market capitalization. That might mean balance sheet strength is important to the business, but should also help push the P/E a bit higher than it would otherwise be.

The Verdict On PetMed Express’s P/E Ratio

PetMed Express’s P/E is 11.6 which is below average (18.1) in the US market. It grew its EPS nicely over the last year, and the healthy balance sheet implies there is more potential for growth. The below average P/E ratio suggests that market participants don’t believe the strong growth will continue.

Investors have an opportunity when market expectations about a stock are wrong. If the reality for a company is not as bad as the P/E ratio indicates, then the share price should increase as the market realizes this. So this free visualization of the analyst consensus on future earnings could help you make the right decision about whether to buy, sell, or hold.

Of course you might be able to find a better stock than PetMed Express. So you may wish to see this free collection of other companies that have grown earnings strongly.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.